// App-Quantinova.ai

53 : Real-world survival of men with metastatic hormone-sensitive prostate cancer (mHSPC) treated with abiraterone acetate (Abi) or docetaxel (Doc) and comparison with clinical trial outcomes.

Researchers

Presenter

  • Daniel M. Geynisman

Principal Investigators

  • Andres F Correa

  • Chethan Ramamurthy

  • J Robert Beck

  • Elizabeth A. Handorf

Medical Centers

  • Fox Chase Cancer Center, Philadelphia, PA

  • Fox Chase Cancer Center, Philadelphia, PA

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Prostate cancer

Biomarkers

  • Prostate specific antigen

Drug/Treatment

  • CB-7598

  • Docetaxel

Outcome

  • N/A

Study Design

  • Observational

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved